After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than ...
The phase 3 KANDLELIT-007 trial (NCT07190248) evaluating the KRAS G12C inhibitor calderasib (MK-1084) plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; SC pembrolizumab) ...
IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparatorIM1240's ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...
Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or ...
Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) Both studies achieved secondary endpoint of ...
Mereo BioPharma (MREO) announced results from the Phase 3 ORBIT and COSMIC studies for setrusumab in Osteogenesis Imperfecta. Neither study ...
Cidara Therapeutics skyrockets 1,165% after positive CD388 data and Merck's acquisition bid. Read why CDTX stock is a Hold.
Claimed as the first space qualified 3-GHz phase locked loop ICs, the PE9701 and PE9702 are integer-N PLLs featuring 10/11 dual modulus pre-scalers, phase comparators and counter values targeted at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback